Circulating levels of receptor activator of nuclear factor-κB ligand/osteoprotegerin/macrophage-colony stimulating factor in a presumably healthy human population

European Journal of Endocrinology

Volumn 150, Issue 3, 2004, Pages 305-311

  Trofimov, Svetlana ^a   Pantsulaia, Ia ^a,b   Kobyliansky, Eugene ^a   Livshits, Gregory ^a  

^a TEL AVIV UNIVERSITY   (Israel)

^b INSTITUTE OF PHYSICS   (Georgia)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; COLONY STIMULATING FACTOR; CYTOKINE; EDETIC ACID; ESTRADIOL; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN; SEX HORMONE;

ADULT; AGE; AGED; ARTICLE; BLOOD LEVEL; BLOOD SAMPLING; BONE DISEASE; COHORT ANALYSIS; CONTROLLED STUDY; CORRELATION ANALYSIS; DIET RESTRICTION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GENDER; GROUPS BY AGE; HUMAN; HUMAN EXPERIMENT; MALE; MATHEMATICAL MODEL; MENOPAUSE; NORMAL HUMAN; PRIORITY JOURNAL; STATISTICAL SIGNIFICANCE;

ADOLESCENT; ADULT; AGE FACTORS; AGED; BONE DENSITY; CARRIER PROTEINS; COHORT STUDIES; ENZYME-LINKED IMMUNOSORBENT ASSAY; ESTRADIOL; FEMALE; HUMANS; MACROPHAGE COLONY-STIMULATING FACTOR; MALE; MEMBRANE GLYCOPROTEINS; MIDDLE AGED; RADIOIMMUNOASSAY; RANK LIGAND; RECEPTOR ACTIVATOR OF NUCLEAR FACTOR-KAPPA B; SEX FACTORS; STATISTICS, NONPARAMETRIC; TESTOSTERONE;

EID: 1842579512     PISSN: 08044643     EISSN: None     Source Type: Journal    
DOI: 10.1530/eje.0.1500305     Document Type: Article

References (34)

1. Walsh MC & Choi Y. Biology of the TRANCE axis. Cytokine and Growth Factor Reviews 2003 14 51-63.
2. Hofbauer L, Khosla S, Dunstan C, Lacey L, Boyle W & Riggs B. The roles of osteoprotegerin and osteoprotegerin ligand in the paracrine regulation of bone resorption. Journal of Bone and Mineral Research 2000 15 2-12.
3. Ross F & Teitelbaum S. Osteoclast biology. In Osteoporosis, pp 73-105. Eds D Feldman & J Kelsey. San Diego: Academic Press, 2001.
4. Brown J, Vessella R, Kostenuik P, Dunstan C, Lange P & Corey E. Serum osteoprotegerin levels are increased in patients with advanced prostate cancer. Clinical Cancer Research 2001 10 977-983.
5. Teng Y, Nguyen H, Gao X, Kong Y, Gorczynski R, Singh B et al. Functional human T-cell immunity, and osteoprotegerin ligand control alveolar bone destruction in periodontal infection. Journal of Clinical Investigation 2000 106 R59-R67.
6. Feuerherm A, Borset M, Seidel C, Sundan A, Leistad L, Ostensen M et al. Elevated levels of osteoprotegerin (OPG) and hepatocyte growth factor (HGF) in rheumatoid arthritis. Scandinavian Journal of Rheumatology 2001 30 229-234.
7. Bekker P, Holloway D, Nakanishi A, Arrighi M, Leese P & Dunstan C. The effect of a single dose of osteoprotegerin in postmenopausal women. Journal of Bone and Mineral Research 2001 16 348-360.
8. Hofbauer L, Hicok K, Chen D & Khosla S. Regulation of osteoprotegerin production by androgens and anti-androgens in human osteoblastic lineage cells. European Journal of Endocrinology 2002 147 269-273.
9. Khosla S, Atkinson EJ, Dunstan C & O'Fallon W. Effect of estrogen versus testosterone on circulating osteoprotegerin and other cytokine levels in normal elderly men. Journal of Clinical Endocrinology and Metabolism 2002 87 1550-1554.
10. Bord S, Ireland D, Beavan S & Compston J. The effects of estrogen on osteoprotegerin, RANKL, and estrogen receptor expression in human osteoblasts. Bone 2003 32 136-141.
11. Khosla S, Arrighi H, Melton LJ III, Atkinson E, O'Fallon W, Dunstan C et al. Correlates of osteoprotegerin levels in women and men. Osteoporosis International 2002 13 394-399.
12. Szulc P, Hofbauer LC, Heufelder AE, Roth S & Delmas P. Osteoprotegerin serum levels in men: Correlation with age, estrogen, and testosterone status. Journal of Clinical Endocrinology and Metabolism 2001 86 3162-3165.
13. Yano K, Tsuda E, Washida N, Kobayashi F, Goto M, Harada A et al. Immunological characterization of circulating osteoprotegerin/osteoclastogenesis inhibitory factor: Increased serum concentrations in postmenopausal women with osteoporosis. Journal of Bone and Mineral Research 1999 14 518-527.
14. Rogers A, Saleh G, Hannon RA, Greenfield D & Eastell R. Circulating estradiol and osteoprotegerin as determinants of bone turnover and bone density in postmenopausal women. Journal of Clinical Endocrinology and Metabolism 2002 87 4470-4475.
15. Fahrleitner-Pammer A, Dobnig H, Piswanger-Soelkner C, Bonelli C, Dimai HP, Leb G et al. Osteoprotegerin serum levels in women: correlation with age, bone mass, bone turnover and fracture status. Wiener Klinische Wochenschrift 2003 115 291-297.
16. Jung K, Lein M, Hosslin K, Grosse A, Roth S, Possinger K et al. Osteoprotegerin and receptor activator of nuclear factor-kappaB ligand (RANKL) in the serum of healthy adults. International Journal of Biological Markers 2002 17 177-181.
17. Livshits G, Karasik D & Kobyliansky E. Complex segregation analysis of the radiographic phalanges bone mineral density and their age-related changes. Journal of Bone and Mineral Research 2002 17 152-161.
18. Livshits G, Yakovenko C & Kobyliansky E. Quantitative genetic analysis of circulating levels of biochemical markers of bone formation. American Journal of Medical Genetics 2000 94 324-331.
19. Sartoris DJ. Quantitative bone mineral analysis. In Bone and Joint Imaging, edn 2, pp 154-164. Ed. D Resnick. Philadelphia, PA: WB Saunders Co., 1996.
20. Ziolkowska M, Kurowska M, Radzikowska A, Luszczykiewicz G, Wiland P, Dziewczopolski W et al. High levels of osteoprotegerin and soluble receptor activator of nuclear factor kappa B ligand in serum of rheumatoid arthritis patients and their normalization after anti-tumor necrosis factor alpha treatment. Arthritis and Rheumatism 2002 46 1744-1753.
21. Malkin I, Karasik D, Livshits G & Kobyliansky E. Modelling of age-related bone loss using cross-sectional data. Annals of Human Biology 2002 29 256-270.
22. Suda T, Kobayashi K, Jimi E, Udagawa N & Takahashi N. The molecular basis of osteoclast differentiation and activation. Novartis Foundation Symposium 2001 232 247-250.
23. Quinn J, Elliott J, Gillespie M & Martin T. A combination of osteoclast differentiation factor and macrophage-colony stimulating factor is sufficient for both human and mouse osteoclast formation in vitro. Endocrinology 1998 139 4424-4427.
24. Saika M, Inoue D, Kido S & Matsumoto T. 17beta-estradiol stimulates expression of osteoprotegerin by a mouse stromal cell line, ST-2, via estrogen receptor-alpha. Endocrinology 2001 142 2205-2212.
25. Kudlacek S, Schneider B, Woloszczuk W, Pietschmann P & Willvonseder R. Serum levels of osteoprotegerin increase with age in a healthy adult population. Bone 2003 32 681-686.
26. Ueland T, Bollerslev J, Godang K, Muller F, Froland S & Aukrust P. Increased serum osteoprotegerin in disorders characterized by persistent immune activation or glucocorticoid excess - possible role in bone homeostasis. European Journal of Endocrinology 2001 145 685-690.
27. Shiotani A, Takami M, Itoh K, Shibasaki Y & Sasaki T. Regulation of osteoclast differentiation and function by receptor activator of NF-κB ligand and osteoprotegerin. Anatomical Record 2002 268 137-146.
28. Nagai M, Kyakumoto S & Sato N. Cancer cells responsible for humoral hypercalcemia express mRNA encoding a secreted form of ODF/TRANCE that induces osteoclast formation. Biochemical and Biophysical Research Communications 2000 269 532-536.
29. Alvarez L, Peris P, Guanabens N, Vidal S, Ros I, Pons F et al. Serum osteoprotegerin and its ligand in Paget's disease of bone: relationship to disease activity and effect of treatment with bisphosphonates. Arthritis and Rheumatism 2003 48 824-828.
30. Terpos E, Szydlo R, Apperley JF, Hatjiharissi E, Politou M, Meletis J et al. Soluble receptor activator of nuclear factor κB ligand-osteoprotegerin ratio predicts survival in multiple myeloma: proposal for a novel prognostic index. Blood 2003 102 1064-1069.
31. Jung K, Lein M, Hösslin K, Grosse A, Roth S, Possinger K et al. Osteoprotegerin and receptor activator of nuclear factor-κB ligand in serum of healthy adults. International Journal of Biological Markers 2002 17 177-181.
32. Motoyoshi K. Biological activities and clinical application of M-CSF. International Journal of Hematology 1998 67 109-122.
33. Kamada M, Irahara M, Maegawa M, Ohmoto Y, Takeji T, Yasui T et al. Postmenopausal changes in serum cytokine levels and hormone replacement therapy. American Journal of Obstetrics and Gynecology 2001 184 309-314.
34. Hasegawa Y, Sawada M, Ozaki N, Inagaki T & Suzumura A. Increased soluble tumor necrosis factor receptor levels in the serum of elderly people. Gerontology 2000 46 185-188.